Development and Characterization of Solid Dispersion-Based Oral Formulations of Febuxostat for Improved Dissolution and Release Performance: A Review

Poor aqueous solubility is among the most persistent obstacles in oral drug development, since a large fraction of contemporary drug candidates dissolve too slowly to be reliably absorbed. Febuxostat, a non-purine selective xanthine-oxidase inhibitor used in the chronic management of gout and hyperuricaemia, exemplifies this problem: it is a Biopharmaceutics Classification System (BCS) Class II compound that combines high intestinal permeability with very low aqueous solubility, so its absorption is dissolution-rate limited and its bioavailability can be variable. This review examines the rationale, scientific principles, formulation strategies, and characterization framework for solid dispersion-based oral formulations designed to improve the dissolution and release performance of febuxostat. The molecular and physicochemical profile of the drug—its weakly acidic, pH-dependent solubility and its tendency to polymorphism—is related to the mechanisms by which solid dispersions enhance dissolution, namely reduction of crystallinity, conversion to the amorphous state, increased surface area, improved wettability, and the generation and maintenance of supersaturation. The principal hydrophilic carriers used in such systems, including polyvinylpyrrolidone (PVP K30), polyethylene glycol (PEG 6000), hydroxypropyl methylcellulose (HPMC), and Soluplus, are reviewed alongside the main preparation techniques—solvent evaporation, fusion, hot-melt extrusion, spray drying, freeze drying, and co-precipitation—and their comparative merits. The solid-state and dissolution characterization framework (FTIR, DSC, PXRD, SEM, and in-vitro dissolution) and the central problem of physical stability against recrystallization are discussed. The evidence indicates that a rationally selected carrier and preparation method can convert crystalline febuxostat into a stable amorphous dispersion that markedly accelerates dissolution and improves release consistency, providing a sound and scalable basis for enhanced oral delivery of this and other BCS Class II drugs.